Understand what your heart cardiovascular testing results really mean
See your biomarkers in context with a comprehensive panel.
- CLIA-certified labs
- HIPAA compliant
- Personalized health protocol
Vascular dementia and the markers that trace brain vessel health
Vascular dementia arises when brain blood vessels are damaged, reducing blood flow and disrupting the cells that support thinking. Blood biomarkers make this hidden vascular injury visible, turning complex biology into signals that can be monitored. They capture stress on the vessel lining and small vessels (endothelial dysfunction; sICAM‑1, sVCAM‑1), leakage of the blood–brain barrier (MMP‑9), astroglial responses (GFAP, S100B), and downstream injury to nerve fibers (neurofilament light, NfL). Inflammation and clotting signals (CRP, IL‑6, fibrinogen, homocysteine) reflect systemic forces that drive small‑vessel disease. Together, these markers help detect vascular brain injury earlier, gauge ongoing activity, and separate it from primary Alzheimer‑type changes; pairing vascular signals with amyloid and tau measures (Aβ, p‑tau) clarifies whether cognitive decline is vascular, neurodegenerative, or mixed. In short, vascular dementia biomarkers translate blood into a picture of neurovascular health, enabling risk stratification, tracking over time, and targeted prevention focused on protecting the brain’s circulation (neurovascular unit).
Why measuring vascular risk matters for cognition
Vascular dementia blood biomarkers capture how your blood vessels, immune system, and liver-driven lipoproteins are shaping blood flow to the brain. They spotlight atherogenic particle burden (LDL cholesterol and ApoB), inherited risk (Lp[a]), and vascular inflammation (hs‑CRP)—factors that drive small‑vessel disease, microinfarcts, and white‑matter injury that slow thinking and impair gait and mood. In most labs, desirable cut‑points cluster toward the low end: LDL under 100, ApoB under 80–90, Lp(a) under 30, and hs‑CRP under 1. “Typical” mid‑range LDL or ApoB can still permit artery aging, especially if hs‑CRP sits in the middle to high end. Men tend to accrue risk earlier; women’s risk accelerates after menopause. In youth, persistently high ApoB/LDL seeds vascular changes decades before symptoms. When these numbers are low, blood is less injurious to vessel linings, perfusion to deep brain tissue is steadier, and white‑matter pathways are better preserved—making cognitive slowing less likely. Very low lipids can occasionally reflect conditions like hyperthyroidism, malabsorption, or severe illness, sometimes accompanied by weight loss, palpitations, or fatigue; low hs‑CRP simply signals quiet inflammation. Higher values point to more particle entry into vessel walls and active inflammation: small‑artery narrowing, microinfarcts, and white‑matter changes that show up as slower processing, poor multitasking, gait instability, urinary urgency, mood shifts, and a stepwise decline. Elevated Lp(a) adds thrombotic tendency and plaque complexity. Pregnancy can transiently raise lipids and hs‑CRP, while postmenopause levels often rise. Big picture: these markers connect liver metabolism, genetics, and immune tone to cerebrovascular integrity. Alongside blood pressure, glucose, and kidney function, they forecast stroke risk, silent brain injury, and the long‑term trajectory toward vascular dementia—often years before symptoms emerge.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
What a vascular risk panel can and can't tell you about dementia
Dementia (Vascular) blood testing provides insight into the health of your blood vessels and how well your brain is supplied with oxygen and nutrients. Vascular dementia is closely linked to the health of the cardiovascular system, which affects not only cognition but also energy, metabolism, and overall system stability. At Superpower, we test LDL cholesterol, ApoB, Lp(a), and hs-CRP to assess key aspects of vascular health that influence dementia risk. LDL (low-density lipoprotein) is often called “bad cholesterol” because high levels can lead to plaque buildup in arteries, restricting blood flow to the brain. ApoB (apolipoprotein B) is a protein found on LDL particles and provides a more precise count of these cholesterol-carrying particles. Lp(a), or lipoprotein(a), is a genetic variant of LDL that is particularly atherogenic, meaning it can accelerate plaque formation. hs-CRP (high-sensitivity C-reactive protein) is a marker of inflammation, which can damage blood vessels and contribute to both heart disease and vascular dementia. Healthy levels of LDL, ApoB, and Lp(a) support stable blood flow and reduce the risk of small vessel damage in the brain, which is crucial for maintaining cognitive function. Low hs-CRP indicates minimal inflammation, supporting the integrity of blood vessels and reducing the risk of vascular injury that can lead to dementia. Interpretation of these biomarkers can be influenced by age, acute illness, chronic conditions, medications, and even laboratory methods. For example, levels may shift during infections, pregnancy, or with certain therapies, so results are best understood in the context of your overall health.
Frequently Asked Questions
References
- O'Brien JT, Thomas A (2015). Vascular dementia. *The Lancet*, *386*(10004), 1698-1706. https://doi.org/10.1016/S0140-6736(15)00463-8
- Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, ... Catapano AL (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *European Heart Journal*, *38*(32), 2459-2472. https://doi.org/10.1093/eurheartj/ehx144
- Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, ... Catapano AL (2022). Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement. *European Heart Journal*, *43*(39), 3925-3946. https://doi.org/10.1093/eurheartj/ehac361
- Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J (2010). C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. *The Lancet*, *375*(9709), 132-140. https://doi.org/10.1016/S0140-6736(09)61717-7
- Anstey KJ, Ashby-Mitchell K, Peters R (2017). Updating the evidence on the association between serum cholesterol and risk of late-life dementia: Review and meta-analysis. *Journal of Alzheimer's Disease*, *56*(1), 215-228. https://doi.org/10.3233/JAD-160826
